Metraipolis › archive › dc_25aeecbd1afc

Adrogolide — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/Adrogolide
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-07T16:04:49.443Z
SHA-256 of the archived text
62f58eea8664f235f433b0a3ca8116b2e2e6086dc35ae29527a7adccc3d63cbf
Stable URL of this page
https://metraipolis.com/documento/dc_25aeecbd1afc

How to cite

Adrogolide — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/Adrogolide (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_25aeecbd1afc (Metraipolis archive dc_25aeecbd1afc, sha256 62f58eea8664f235f433b0a3ca8116b2e2e6086dc35ae29527a7adccc3d63cbf)
BibTeX
@misc{dc25aeecbd1afc,
  title = {Adrogolide — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/Adrogolide},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_25aeecbd1afc; sha256 62f58eea8664f235f433b0a3ca8116b2e2e6086dc35ae29527a7adccc3d63cbf},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/Adrogolide. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Adrogolide (INNTooltip International Nonproprietary Name; developmental code names A-93431, ABT-431, and DAS-431), also known as adrogolide hydrochloride (USANTooltip United States Adopted Name) in the case of the hydrochloride salt, is a dopamine D1-like receptor agonist which was under development for the treatment of Parkinson's disease, cognition disorders, and cocaine-related disorders but was never marketed. It is a chemically stable and rapidly converted diacetate ester prodrug of the highly selective dopamine D1 and D5 receptor full agonist A-86929. The effects of adrogolide and A-86929 in animals and humans have been studied. Side effects of adrogolide in humans included injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness. Adrogolide was under development by Abbott Laboratories and DrugAbuse Sciences. It reached phase 2 clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001. The drug is said to have been the first extensively characterized dopamine D1 receptor full agonist.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «Adrogolide» — https://en.wikipedia.org/wiki/Adrogolide
Wikidata Q27294442: «composto chimico» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q27294442
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/Adrogolide?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1374478837, consultata il 2026-11-07T16:01:23.749Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: ddf075a120ffce8a0cc6af9998f5dc1caad80cac2d88c9ed103ed2b0c0603513